# Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult Participants

> **NCT06346509** · PHASE1 · COMPLETED · sponsor: **Portal Therapeutics, Inc.** · enrollment: 156 (actual)

## Conditions studied

- Healthy Adult Participants

## Interventions

- **DRUG:** PORT-77
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06346509
- **Lead sponsor:** Portal Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-08
- **Primary completion:** 2025-12-27
- **Final completion:** 2026-01-20
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06346509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06346509, "Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06346509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*